SLM offers recovery potential through low valuation multiples, strong private education loan demand, and share repurchases, but rising credit provisions and weaker net interest margins threaten sustainable earnings.
Meritage Homes offers an attractive book-value discount and disciplined shareholder returns, but persistent mortgage affordability pressures and weakening homebuilding margins could delay an earnings recovery.
Indivior combines a profitable, growing addiction-treatment franchise with potential Supernus merger synergies, but weak cash conversion, new financing obligations, and integration uncertainty constrain its investment appeal.
VSE can compound aviation aftermarket earnings through specialized repairs, OEM partnerships, and PAG integration, but acquisition-related dilution and weak free cash conversion threaten shareholder returns.
Graham offers diversified operating businesses and substantial investment assets that support long-term per-share value, but uneven cash conversion, Kaplan's education weakness, and a historical valuation premium constrain near-term upside.
Bausch + Lomb's established eye health franchise and improving premium product mix support earnings recovery, but substantial leverage, weak historical cash conversion and controlling-shareholder uncertainty limit investment upside.
Floor & Decor can compound through specialty flooring market-share gains, national store expansion, and professional customer growth, but weak renovation demand and capital-intensive expansion constrain near-term returns.
Suzano's global pulp cost leadership and expanding tissue business offer cyclical recovery potential, but elevated leverage and volatile commodity pricing constrain the margin of safety.
Avnet offers leveraged exposure to an electronics distribution recovery at a modest forward earnings multiple, but negative cash flow, elevated working-capital requirements, and cyclical demand create meaningful downside risk.
Corcept's expanding oncology franchise and proprietary cortisol-modulation pipeline could drive sustained pharmaceutical growth, but regulatory uncertainty and demanding cash-flow valuation constrain the near-term investment opportunity.
Avantor offers a laboratory-supply turnaround supported by recurring demand and improving organic growth, but weak capital returns, distribution margin pressure, and leverage limit near-term upside.
Lithia Motors offers inexpensive exposure to dealership consolidation, resilient aftersales profits, and substantial buybacks, but weak cash conversion, financing leverage, and cyclical vehicle demand constrain conviction.